Zymeworks Inc.

📍 Vancouver, Canada🗓 Founded 2003👥 282 employees💰 Last funded Feb 2024
Biotechnology Research🌐 zymeworks.com
Website LinkedIn
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Zymeworks Inc.?
Zymeworks Inc. has 1 investors on record on gritt.io.
When did Zymeworks Inc. last raise funding?
The most recent investment in Zymeworks Inc. recorded on gritt.io was in February 2024.
When was Zymeworks Inc. founded?
Zymeworks Inc. was founded in 2003.
What industry is Zymeworks Inc. in?
Zymeworks Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Zymeworks Inc. based?
Zymeworks Inc. is headquartered in Vancouver, Canada.